ARGX - argenx SE

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
137.13
-0.22 (-0.16%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close137.35
Open140.17
Bid0.00 x 1000
Ask0.00 x 900
Day's Range136.86 - 139.43
52 Week Range63.81 - 150.92
Volume92,464
Avg. Volume157,539
Market Cap5.279B
Beta (3Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-1.73
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est161.47
Trade prices are not sourced from all markets
  • Is argenx SE's (EBR:ARGX) CEO Paid Enough Relative To Peers?
    Simply Wall St.

    Is argenx SE's (EBR:ARGX) CEO Paid Enough Relative To Peers?

    Tim Van Hauwermeiren has been the CEO of argenx SE (EBR:ARGX) since 2008. This report will, first, examine the CEO...

  • GlobeNewswire

    argenx to Present at 2019 Wedbush PacGrow Healthcare Conference

    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 10:55 am ET in New York. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.

  • GlobeNewswire

    argenx reports half year 2019 financial results and second quarter business update

    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its financial results for the first half of 2019 and provided its second quarter business update and the outlook for the remainder of the year. "We continue to execute on accelerating and expanding our robust, late-stage innovative clinical development programs, as we invest in forward integration across our organization to maximize value. Enrollment for the Phase 3 ADAPT trial in generalized myasthenia gravis is progressing as planned, and we are on track to initiate before the end of the year the first of two pivotal Phase 3 trials, ADVANCE, for our global primary immune thrombocytopenia program, as well as a Phase 2 trial in chronic inflammatory demyelinating polyneuropathy.

  • GlobeNewswire

    argenx to report half year 2019 financial results and second quarter business update on August 1, 2019

    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 1, 2019 at 3:00 pm CEST (9:00 am ET) to discuss its financial results for the first half of 2019 and to provide a second quarter business update and outlook for the remainder of the year. To participate in the conference call and Q&A session, please select your phone number below and use the confirmation code 7539308. Please dial in 5–10 minutes prior to 3 pm CEST/ 9 am ET using the number and confirmation code below.

  • Here's Why Momentum Investors Will Love ARGENX SE-ADR (ARGX)
    Zacks

    Here's Why Momentum Investors Will Love ARGENX SE-ADR (ARGX)

    Does ARGENX SE-ADR (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Here’s What Hedge Funds Think About argenx SE (ARGX)
    Insider Monkey

    Here’s What Hedge Funds Think About argenx SE (ARGX)

    Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]

  • How Does argenx SE (EBR:ARGX) Affect Your Portfolio Volatility?
    Simply Wall St.

    How Does argenx SE (EBR:ARGX) Affect Your Portfolio Volatility?

    If you're interested in argenx SE (EBR:ARGX), then you might want to consider its beta (a measure of share price...

  • Benzinga

    The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...

  • GlobeNewswire

    argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day

    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, will be hosting its second R&D Day today, Wednesday, May 22, 2019, in New York starting at 8:30am ET. During the event, argenx will present data on two new pipeline candidates that emerged from its Innovative Access Program (IAP) and will provide updates on the development plan of cusatuzumab (ARGX-110) in collaboration with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson.

  • Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
    GuruFocus.com

    Eaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks

    Fund releases 1st-quarter portfolio

  • Did Hedge Funds Drop The Ball On argenx SE (ARGX) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On argenx SE (ARGX) ?

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Has argenx SE (EBR:ARGX) Got Enough Cash?
    Simply Wall St.

    Has argenx SE (EBR:ARGX) Got Enough Cash?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as argenx SE (EBR:ARG...

  • ACCESSWIRE

    argenx SE ADR to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 28, 2019 / argenx SE ADR (NASDAQ: RGX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 at 9:00 AM Eastern ...

  • argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
    PR Newswire

    argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology

    BREDA, the Netherlands and GHENT, Belgium and SAN DIEGO, Feb. 4, 2019 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme's ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement provides argenx exclusive access to ENHANZE® for any product targeting the human neonatal Fc receptor FcRn, including argenx's lead asset efgartigimod (ARGX-113) and up to two additional targets, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients. Under the terms of the agreement, argenx will pay an upfront payment of $30 million to Halozyme, $10 million per target for future target nominations and potential future payments of up to $160 million per selected target subject to achievement of specified development, regulatory and sales-based milestones.

  • GlobeNewswire

    argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

    Breda, the Netherlands / Ghent, Belgium & San Diego – argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme’s ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx product candidates. The agreement provides argenx exclusive access to ENHANZE® for any product targeting the human neonatal Fc receptor FcRn, including argenx’s lead asset efgartigimod (ARGX-113) and up to two additional targets, potentially shortening drug administration time, reducing healthcare practitioner time, and offering additional flexibility and convenience for patients. Under the terms of the agreement, argenx will pay an upfront payment of $30 million to Halozyme, $10 million per target for future target nominations and potential future payments of up to $160 million per selected target subject to achievement of specified development, regulatory and sales-based milestones.

  • ACCESSWIRE

    Today's Research Reports on Trending Tickers: Editas Medicine and argenx

    NEW YORK, NY / ACCESSWIRE / January 23, 2019 / U.S. markets declined on Tuesday, breaking a streak of four consecutive days in the green, on growing trade concerns. Stocks were pressured lower on reports ...

  • Who Has Been Selling argenx SE (EBR:ARGX) Shares?
    Simply Wall St.

    Who Has Been Selling argenx SE (EBR:ARGX) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...

  • Benzinga

    6 Valuable Pipeline Drugs With Upcoming Catalysts

    Heading into December, biotech stocks held up fairly well in 2018. Evaluate Pharma , a firm specializing in data-driven news and analysis in biotech, compiled a list of blockbuster drugs in the works with ...

  • Reuters

    Dutch firm argenx, J&J affiliate to collaborate on cancer therapy

    Netherlands-based biopharmaceutical company argenx SE said it signed a deal with Cilag GmbH International, an affiliate of Johnson & Johnson's Janssen Pharmaceutical Companies unit, to develop its Cusatuzumab drug in certain types of cancer. The deal, which is potentially worth up to $1.6 billion, represents a global collaboration and licensing agreement for the cancer drug Cusatuzumab, the company said. Janssen will pay argenx $300 million in upfront cash payment, while Johnson & Johnson Innovation will make an equity investment of $200 million in argenx, the company said.

  • GlobeNewswire

    argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced  that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP)  and the Phase 1 portion of its Phase 1/2 clinical trial of cusatuzumab (ARGX-110) in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) during a workshop being held in conjunction with the 60th American Society of Hematology (ASH) Annual Meeting and Exposition. The workshop is being held on Monday, December 3, 2018 at 12:00 p.m. PT.

  • GlobeNewswire

    argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)

    Regulated information – Inside information Collaboration to develop cusatuzumab in AML, MDS and other hematological malignancies in deal totaling up to $1.6 billion.

  • GlobeNewswire

    argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition

    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced updated data from the ongoing Phase 1 dose-escalation part of its Phase 1/2 clinical trial of cusatuzumab (ARGX-110) in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). As of the data cut-off on July 16, 2018, a 92% (11/12 patients) overall response rate (ORR) was observed, with 42% of patients achieving minimal residual disease (MRD) negativity. Data from this ongoing AML trial are expected to be further updated, including ORR and duration of response, during a company workshop to be held around the American Society of Hematology (ASH) Annual Meeting.

  • Simply Wall St.

    Is argenx SE’s (EBR:ARGX) Liquidity Good Enough?

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like argenx SE (EBR:ARGX), with a market cap of €2.5b, are often out of the spotlight. Read More...